	US 12,378,310 B2
	Antibodies specific to folate receptor alpha
Bing Hou, Shanghai (CN); Na Wang, Shanghai (CN); and Xun Meng, Shanghai (CN)
Assigned to Multitude Inc., Shanghai (CN)
Filed by Multitude Inc., Shanghai (CN)
Filed on Jan. 8, 2021, as Appl. No. 17/144,588.
Application 17/144,588 is a continuation of application No. PCT/IB2019/000873, filed on Jun. 26, 2019.
Claims priority of provisional application 62/695,535, filed on Jul. 9, 2018.
Prior Publication US 2021/0284726 A1, Sep. 16, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); G01N 33/574 (2006.01)

CPC C07K 16/28 (2013.01) [A61K 47/6849 (2017.08); G01N 33/57492 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)]

20 Claims

1. An isolated antibody that binds to FOLR1, wherein the isolated antibody comprises a heavy chain variable region (V_H) comprising a heavy chain complementary determining region 1 (HC CDR1) of the amino acid sequence of SEQ ID NO: 8, a HC CDR2 of the amino acid sequence of SEQ ID NO: 11, and a HC CDR3 of the amino acid sequence of SEQ ID NO: 14, and a light chain variable region (V_L) comprising a light chain CDR1 (LC CDR1) of the amino acid sequence of SEQ ID NO: 5, a LC CDR2 of the amino acid sequence WAS, and a LC CDR3 of the amino acid sequence of SEQ ID NO: 19.